Post-earnings recap
Reported
Thu, Feb 26, 2026
EPS actual
$-4.66
EPS est.
$-1.34
EPS surprise
-248.02%
1-day move
+1.61%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Vera Therapeutics reported a significant loss per share, which was not unexpected as no prior guidance was provided. Despite the disappointing EPS, the stock rose by 1.61%, possibly due to market optimism or other external factors. Investors may be looking for signs of recovery in future quarters, but the lack of guidance leaves uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-4.66 | N/A | -248.02% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over the current financial performance. They did not offer any forward guidance, indicating uncertainty about upcoming quarters.
Management acknowledged the significant loss per share.
No specific guidance was provided for future quarters.